DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
This application is a continuation of Application No. 17/479230 (filed on 9/20/2021), which is a continuation of Application No. 16/180704 (filed on 11/05/2018), which is a continuation of Application No. 15/887651 (filed on 2/02/2018), which is a continuation of Application No. 15/155628 (filed on 5/16/2016), which in turn claims priority benefit of U.S. Provisional Application No. 62/161826 (filed on 5/14/2015) under 35 U.S.C. 119(e).
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 10/28/2024 complies with the provisions of 37 C.F.R. 1.97 and has been fully considered.
Claim Objections
Claim 1 is objected to since a comma is missing after the word “lower” (line 3).
Claim 5 is objected to because the word “dyes” is a noun modifier in the compound noun “dyes stains” and should therefore be amended to “dye”.
Claim 6 is objected to due to the following informality: the abbreviation for hydroxypropyl-β-cyclodextrin should be “HP-β-CD”.
Claim 14 is objected to since space is missing between the numerical value and the corresponding unit in “200mg”. In addition, an abbreviation (“cfu”) is used without providing the full form. Any abbreviation should be defined when first recited in a set of claims by spelling out the full term followed by the abbreviation in parentheses. It is recommended that “cfu” be amended to “colony forming units (CFU)”.
Claim 15 is objected to because the recited group of treatments should use the conjunction “and” (not “or”) before the last alternative. To rectify this minor informality, the phrase “irradiation, and sonication, or a combination thereof” should be amended to “irradiation, sonication, and a combination thereof”.
Claim 16 is objected to because of the following informality: “filtering” and “filtration” are synonyms. One of these terms should be deleted to avoid redudancy.
Claims 18-19 are objected to since the abbreviation for the bacterial species Clostridium difficile is not “C. diff.” and should be replaced with “C. difficile”.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
Claims 1-6 and 12-19 are rejected under 35 U.S.C. 112(a) as based on a disclosure which is not enabling.
The invention is directed to a pharmaceutical composition comprising a fecal microbiota preparation in a lyophilized formulation. Cell viability is specified to be at least 60% in claim 1 (or about 60% to about 80% in claim 2) after at least 12 weeks of storage at ambient temperature, relative to the initial cell viability immediately prior to storage. Ambient temperature is defined by the applicant as referring to the temperature of the surrounding air, which is between 15[Symbol font/0xB0]C and 22[Symbol font/0xB0]C inside a temperature-controlled building (paragraph [0021], Specification).
A cryoprotectant is critical to the practice of the invention, but not included in the claims, is not enabled by the disclosure. According to MPEP 217.01, “A claim which omits matter disclosed to be essential to the invention as described in the specification or in other statements of record may be rejected under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph, as not enabling.” See In re Mayhew, 527 F.2d 1229, 188 USPQ 356 (CCPA 1976).
The recited property of the pharmaceutical composition maintaining at least 60% cell viability (or about 60% to about 80%) after at least 12 weeks of storage at ambient temperature relies on the addition of at least one cryoprotectant which protects an active ingredient (i.e. fecal microbiota) during freezing. Specification states that an intracellular cryoprotectant like glycerol penetrates inside the cell and inhibits ice crystal formation that can cause membrane rupture. An extracellular cryoprotectant like trehalose, on the other hand, improves the osmotic imbalance during freezing (par. [0040], page 7). Based on what is known in the art, a fecal microbiota would not be able to remain viable for several weeks at ambient temperature without any cryoprotectant since cellular damage would be incurred during freezing and thawing.
In the instant application, a working example (Example 2, par. [00191]-[00200]) is demonstrates the effect of either trehalose or mannitol in combination with sucrose and/or polysorbate 80, in maintaining the viability of lyophilized fecal microbiota after storage at ambient temperature, 4[Symbol font/0xB0]C, and 80[Symbol font/0xB0]C for 4 weeks (Figures 5-6) or 12 weeks (Figure 7-8). It is noted that only trehalose has been demonstrated to maintain at least 60% cell viability (or about 60-80%) relative to the initial viability immediately prior to storage at ambient temperature for 12 weeks. There is no data showing that other cryoprotectants also have this capability (data for certain cryoprotectant combinations are still pending).
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claims 1-5 and 12-19 are rejected under 35 U.S.C. 112(b) as being incomplete for omitting essential elements, such omission amounting to a gap between the elements. See MPEP § 2172.01. The omitted element is: a cryoprotectant.
Claims 1 and 19 recite the limitation “wherein after at least 12 weeks of storage at ambient temperature or lower said fecal microbiota preparation is capable of maintaining at least 60% cell viability relative to the initial cell viability immediately prior to storage”. However, the claims fail to point out an essential component of the invention, which is a cryoprotectant that preserves the viability of microbial cells. Without a cryoprotectant that can effectively keep cells viable, the fecal microbiota would not be able to achieve the limitation of maintaining a cell viability of at least 60% after at least 12 weeks of storage.
Claims 3-4 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
The term “substantially complete” in claim 3 is a relative term which renders the claim indefinite. The term “substantially complete” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. For example, it is unclear if 50% of the fecal microbiota of a single donor is encompassed by “substantially complete”. Or does the term refer to at least 99% of the donor’s fecal microbiota? Claim 4 is also considered indefinite for depending on claim 3.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-19 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 9,901,603.
The U.S. patent provides a pharmaceutical composition comprising a fecal microbiota preparation in a lyophilized formulation comprising at least 4% trehalose, wherein after at least 12 weeks of storage at ambient temperature, said fecal microbiota preparation is capable of maintaining at least 60% cell viability relative to the initial cell viability immediately prior to storage. In an embodiment, the fecal microbiota preparation is capable of maintaining about 60% to about 80% cell viability relative to the initial cell viability at the start of at least 12 weeks of storage at ambient temperature.
The lyophilized formulation can further comprise one or more cryoprotectants selected from the group consisting of dimethyl sulfoxide (DMSO), glycerol, polyethylene glycol (PEG), alanine, glycine, proline, mannitol, sucrose, glucose, lactose, ribose, hydroxypropyl-β-cyclodextrin (HPβCD), and any combination thereof. One embodiment is that the lyophilized formulation comprises 4-20% trehalose, about 5% trehalose, or both trehalose and sucrose. In some embodiments, the pharmaceutical composition is suitable for oral administration or formulated as a geltab, pill, microcapsule, capsule, or tablet.
The fecal microbiota preparation can be prepared via a treatment selected from the group consisting of ethanol treatment, detergent treatment, heat treatment, irradiation, sonication, and a combination thereof. Moreover, the preparation can involve a separation step selected from the group consisting of filtering, sieving, density gradients, filtration, chromatography, and a combination thereof.
Claims 1-19 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 10,821,138.
U.S. 10,821,138 discloses a pharmaceutical composition comprising a preparation of fecal bacteria in a lyophilized formulation containing a cryoprotectant selected from the group consisting of trehalose, mannitol and sucrose, wherein said preparation of fecal bacteria comprises a community of bacteria derived from a stool of one or more human donors. The preparation of fecal bacteria is capable of maintaining at least 50% cell viability after at least 4 weeks of storage at room temperature relative to the initial cell viability immediately prior to storage. Alternatively, the fecal microbiota preparation is capable of maintaining about 60% to about 80% cell viability relative to the initial cell viability at the start of at least 4 weeks of storage at ambient temperature.
In one aspect, the disclosed composition is specified to be an oral pharmaceutical composition comprising a non-selective preparation of fecal bacteria in a cryoprotectant-containing lyophilized formulation, wherein said cryoprotectant is selected from the group consisting of trehalose, mannitol and sucrose.
In certain embodiments, the cryoprotectant is limited to trehalose and its concentration is at least 2%, at least 5%, or at least 10%. The pharmaceutical composition can be formulated as a geltab, pill, microcapsule, capsule, or tablet.
Claims 1-19 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-41 of U.S. Patent No. 11,123,377.
U.S. 11,123,377 is drawn to a pharmaceutical composition comprising a microbial preparation in a lyophilized formulation which comprises one or more cryoprotectants selected from the group consisting of trehalose, mannitol, sucrose, and any combination thereof. The microbial preparation comprises viable purified microorganisms from two or more genera selected from the group consisting of Akkermansia, Anaerotruncus, Blautia, Clostridium, and Dorea, wherein after at least 4 weeks of storage at room temperature, said microbial preparation is capable of maintaining at least 50% cell viability relative to the initial cell viability immediately prior to storage.
Some embodiments specify that the lyophilized formulation comprises trehalose and it amounts to 6%-10%, at least 5%, or at least 10%. In other embodiments, the cryoprotectant is further defined as comprising at least 2.5% sucrose, at least 5% mannitol, or at least 10% mannitol. Moreover, the pharmaceutical composition can be prepared for oral administration. It can be formulated as a geltab, pill, microcapsule, capsule, or tablet.
Claims 1-19 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 12,161,678.
The U.S. patent is directed to a pharmaceutical composition comprising: (i) a lyophilized microbial preparation comprising Clostridium butyricum and Bifidobacterium infantis, and a cryoprotectant mix comprising sucrose, trehalose, and glycerol; and (ii) a prebiotic, wherein after at least 4 weeks of storage at room temperature, the lyophilized microbial preparation is capable of maintaining at least 50% cell viability relative to the initial cell viability immediately prior to storage.
In one embodiment, the pharmaceutical composition is specified to be lyophilized and comprises: (i) a microbial preparation comprising Clostridium butyricum, Bifidobacterium infantis, and Anaerobutyricum hallii; (ii) a cryoprotectant mix comprising sucrose, trehalose, and glycerol; and (iii) a prebiotic, wherein after at least 4 weeks of storage at room temperature, the microbial preparation is capable of maintaining at least 50% cell viability relative to the initial cell viability immediately prior to storage.
In another embodiment, the lyophilized pharmaceutical composition comprises: (i) a microbial preparation comprising Clostridium butyricum, Bifidobacterium infantis, Anaerobutyricum hallii, and an Akkermansia species; (ii) a formulation comprising sucrose, trehalose, and glycerol; and (iii) inulin, wherein after at least 4 weeks of storage at room temperature, the microbial preparation is capable of maintaining at least 50% cell viability relative to the initial cell viability immediately prior to storage.
For these various embodiments, the pharmaceutical composition can be encapsulated in a capsule.
Conclusion
No claim is allowed.
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Sadowsky et al. (Pub. No. US 2014/0147417 A1).
Sadowsky et al. discloses a composition having an extract or a preparation of human feces and optionally a pharmaceutically acceptable carrier (par. [00099]). The disclosed composition can be in the form of a solid having at least 1x1010 bacteria and further comprise a cryoprotectant, wherein the cryoprotectant includes amino acids and simple sugars like sucrose, glucose, lactose, ribose, and trehalose (par. [0032]). It can be formulated for oral administration (par. [0014]) such as pills, tablets, and capsules (par. [0039].). In an embodiment, the fecal extract is combined with a cryoprotectant and then dried via known forms of evaporative drying such as freeze drying and lyophilization (par. [0049]). However, Sadowsky et al. does not explicitly teach the required cell viability after at least 12 weeks of storage at room temperature.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHELLE F PAGUIO FRISING whose telephone number is (571)272-6224. The examiner can normally be reached Monday-Friday, 8:00 a.m. - 4:00 p.m..
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melenie L. Gordon can be reached at (571) 272-8037. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Michelle F. Paguio Frising/Primary Examiner, Art Unit 1651